Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinical_trial |
conducted for efficacy
seasonal influenza vaccination |
| gptkbp:clinical_use |
prevent influenza infection
|
| gptkbp:contraindication |
severe allergic reaction to vaccine components
|
| gptkbp:dosage_form |
suspension for injection
|
| gptkbp:formulation |
gptkb:liquid
|
| https://www.w3.org/2000/01/rdf-schema#label |
Flu Laval
|
| gptkbp:ingredients |
inactivated influenza virus
|
| gptkbp:is_recommended_for |
adults and children over 6 months
|
| gptkbp:is_vulnerable_to |
varies by season
varies by provider quadrivalent available in pharmacies administered by healthcare professionals ongoing studies for new formulations often covered by insurance studies on long-term effects recommended for high-risk groups do not freeze available in hospitals annual vaccination recommended studies on immune response studies on safety in pregnant women available in clinics recommended for pregnant women recommended for healthcare workers depends on circulating strains first approved in 2005 recommended for elderly studies on effectiveness in children studies on effectiveness in elderly updated formulations annually |
| gptkbp:manufacturer |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:market |
ongoing
|
| gptkbp:marketed_as |
gptkb:Europe
gptkb:North_America |
| gptkbp:packaging |
single-dose vials
multi-dose vials |
| gptkbp:provides_guidance_on |
WHO recommendations
CDC recommendations |
| gptkbp:route_of_administration |
intramuscular injection
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
gptkb:Guillain-Barré_syndrome
allergic reactions fever pain at injection site muscle aches |
| gptkbp:storage |
refrigerated
|
| gptkbp:type |
inactivated influenza vaccine
|
| gptkbp:used_for |
influenza prevention
|
| gptkbp:bfsParent |
gptkb:GSK
|
| gptkbp:bfsLayer |
4
|